Sintilimab plus decitabine for higher-risk treatment-naïve myelodysplastic syndromes: efficacy, safety, and biomarker analysis of a phase II, single-arm trial.

The gene mutation subgroup analysis revealed that the ORR among patients with TP53 mutations was 62.5%, juxtaposed with an ORR of 80.0% in those without such mutations, though this difference did not reach statistical significance.

also in 111,027 other papers